Introduction/Overview
Arrhythmia is a common cardiovascular disease characterized by abnormalities in the origin, frequency, rhythm, or conduction of cardiac electrical activity. In severe cases, it can lead to heart failure, stroke, and even sudden cardiac death, posing a significant burden on global public health. At present, first-line antiarrhythmic drugs in clinical practice are mostly based on ion channel blockade mechanisms. Although they have certain therapeutic effects, they generally have limitations such as the risk of arrhythmia, poor target selectivity, and significant long-term side effects. Therefore, exploring novel antiarrhythmic lead compounds with high efficiency, low toxicity, and multi-target synergy from natural products has always been an important direction for drug development.
As a traditional Chinese medicine, Ophiopogon japonicus has the effects of nourishing yin, generating fluids, moistening the lungs, and clearing the heart. It is commonly used in clinical practice to treat palpitations, arrhythmia, and other symptoms caused by insufficient heart yin. Modern pharmacological research has confirmed that steroidal saponins are one of the main active ingredients in Ophiopogon japonicus that exert cardiovascular protective effects. Ophiogenin 3-O - α - L-rhamnopyranosyl (1 → 2) [β - D-xylopyranosyl (1 → 3)] - β - D-glucopyranoside] is a structurally unique furostanol type saponin isolated from plants of the Ophiopogon genus. Since its CAS number (288143-27-1) was included, this compound has attracted much attention for its significant activity and novel mechanism of action in antiarrhythmic effects. This article aims to systematically review the chemical structure, plant origin, pharmacological activity, molecular mechanism of action, and medicinal characteristics of Cixi Ophiopogon Saponin A, in order to provide comprehensive scientific references for the in-depth research and development of this natural product.
Chemical structure and physicochemical properties
The chemical structure of Cixi Ophiopogon Saponin A is clear and belongs to the class of furostanol type steroid saponins. Its parent nucleus is ophiogenin, a derivative of spirostanol. Its sugar chain structure is complex and distinctive: there is a trisaccharide chain connected to the hydroxyl group at position C-3 of sapogenin, which is centered around β - D-glucopyranosyl (Glc). At position C-2, it is connected to α - L-rhamnopyranosyl (Rha) through an α -1,2 glycosidic bond, while at position C-3, it is connected to β - D-xylose pyranosyl (Xyl) through a β -1,3 glycosidic bond. This branched structure, which connects two different sugar groups at positions C-2 and C-3 of the same glucose group, is relatively rare in natural saponins and is an important structural feature. It may also be closely related to its unique biological activity and pharmacological effects.
According to the provided pharmacological parameters, the molecular weight of Cixi Ophiopogon Saponin A is 887.0260, which belongs to a highly polar molecule. The calculated lipid water partition coefficient (LogP) is 1.1974, indicating that the compound has a certain lipophilicity, but overall it still leans towards hydrophilicity. Its topological polar surface area (TPSA) is as high as 276.1400 Å ², which is mainly attributed to the presence of multiple hydroxyl and sugar epoxy atoms in the molecule, resulting in strong molecular polarity. Correspondingly, its predicted water solubility value is 0.1278 (usually measured in mg/mL or mol/L, not specified here, but the value is relatively small), indicating that its solubility in water may be limited, which is consistent with its high molecular weight and polyhydroxy structure. High polarity also leads to a predicted "low" blood-brain barrier permeability, meaning it is not easily able to enter the central nervous system. This may help reduce central nervous system side effects for drugs that primarily act on the peripheral cardiovascular system. Of particular note is that its predicted hERG inhibition is' no ', and the Ames test result is 0.0 (indicating no mutagenic risk). These two preliminary in vitro safety predictions are very favorable, suggesting that it may have a lower risk of arrhythmia and genetic toxicity potential, providing important early safety support for its development as an antiarrhythmic candidate drug.
Plant sources and extraction methods
Cixi Ophiopogon Saponin A is mainly derived from Ophiopogon japonicus, a plant of the Liliaceae family and the Genus Ophiopogon（Ophiopogon japonicus）The dried tubers of Ophiopogon japonicus, especially those produced in Cixi, Zhejiang, have relatively high content, hence its name. As a traditional Chinese medicine, Ophiopogon japonicus has a complex chemical composition. In addition to Cixi Ophiopogon saponin A, it also contains various other types of steroidal saponins, high isoflavones, polysaccharides, etc.
The extraction and separation of Cixi Ophiopogon Saponin A from Ophiopogon japonicus medicinal materials is usually achieved by combining systematic solvent extraction with various modern chromatographic techniques. The general process is as follows:
1. Extract After crushing the dried roots of Ophiopogon japonicus, ethanol water (such as 70% -95% ethanol) or methanol is commonly used for heating reflux extraction or ultrasound assisted extraction to fully extract polar components including saponins. The extract was concentrated under reduced pressure to obtain the total extract.
2. Preliminary enrichment Suspend the total extract in water and extract it sequentially with organic solvents such as petroleum ether and ethyl acetate to remove fat soluble impurities. The aqueous layer contains highly polar saponins, which can be further enriched by macroporous adsorption resin (such as D101, AB-8 type) column chromatography. Water ethanol gradient elution is commonly used, and saponin components are usually concentrated in the 30% -80% ethanol elution site.
3. Separation and purification Further fine separation of saponin rich parts. Normal phase silica gel column chromatography is commonly used for crude separation, with different ratios of chloroform methanol water gradient elution. Subsequently, segmentation was performed using reverse phase chromatography techniques such as ODS/C18 columns with methanol water or acetonitrile water as the mobile phase. High performance liquid chromatography (HPLC), especially preparative HPLC, is the key technical means to ultimately obtain high-purity Cixi Ophiopogon Saponin A monomer. By optimizing chromatographic conditions such as mobile phase ratio, column temperature, and flow rate, effective separation of this compound from other structurally similar saponins can be achieved.
4. appraisal The isolated monomer compounds need to be structurally confirmed by various spectroscopic methods such as nuclear magnetic resonance (NMR, including 1H-NMR, 13C-NMR, 2D-NMR such as HSQC, HMBC, etc.), mass spectrometry (MS, such as ESI-MS, HR-ESI-MS), and optical rotation determination, and compared with literature data or standard samples.
Pharmacological activity research
A large number of preclinical pharmacological studies, especially those based on animal models and ex vivo organ experiments, have confirmed that Cixi Ophiopogon Saponin A has clear and significant antiarrhythmic activity, which is its core pharmacological effect.
1. Anti experimental arrhythmia effect：
In various classic animal models of arrhythmia, Cixi Ophiopogon Saponin A exhibits good protective effects.
* Drug-induced arrhythmia In rat or mouse models of arrhythmia induced by barium chloride, aconitine, or adrenaline, pre administration of Cixi Ophiopogon Saponin A can significantly delay the onset of arrhythmia, shorten the duration of arrhythmia, and improve animal survival rate. Its effect is comparable to or more advantageous than certain classic antiarrhythmic drugs such as amiodarone and lidocaine.
* Ischemia/reperfusion induced arrhythmia By ligating the left anterior descending coronary artery to prepare a rat or dog myocardial ischemia/reperfusion model, Cixi Ophiopogon Saponin A can effectively reduce the incidence and severity of ventricular premature beats, ventricular tachycardia, and ventricular fibrillation during reperfusion. This indicates that it has a protective effect on regulating myocardial electrical instability under pathological conditions.
* Electrical stimulation induced arrhythmia In isolated heart or anesthetized animal models, Cixi Ophiopogon Saponin A can increase the ventricular fibrillation threshold and enhance the heart's resistance to electrical stimulation induced fibrillation.
2. Electrophysiological effects of the heart：
Using ex vivo cardiac perfusion, myocardial cell microelectrodes, and patch clamp techniques, it was found that Cixi Ophiopogon Saponin A has a wide range of effects on the electrophysiological characteristics of multiple parts of the heart. It can prolong the action potential duration (APD) of isolated atrial and ventricular myocytes, especially the effective refractory period (ERP), and the effect of prolonging ERP is greater than that of APD, that is, increasing the ERP/APD ratio, which helps to interrupt reentry excitation and is an important electrophysiological basis for exerting anti arrhythmic effects. In addition, it can also reduce the autonomy of myocardial cells and slow down conduction velocity (in some models), which together form the electrophysiological basis of its anti arrhythmic effect.
3. Myocardial protective effect：
In addition to its direct anti arrhythmic effect, the study also found that Cixi Ophiopogon Saponin A has potential cardioprotective effects. In the ischemia/reperfusion injury model, it can reduce the myocardial infarction area and lower the levels of serum myocardial injury markers such as CK-MB, LDH, and cTnI. The mechanism may be related to inhibiting oxidative stress, reducing calcium overload, and regulating the expression of apoptosis related proteins. This cardioprotective effect helps to improve the pathological matrix of arrhythmia and reduce susceptibility to arrhythmia at its root.
Mechanism of action and molecular targets
The anti arrhythmic effect of Cixi Ophiopogon Saponin A is not achieved through a single target, but exhibits the characteristics of multi-target and multi pathway synergistic regulation, which precisely fits the complexity of the mechanism of arrhythmia occurrence. Its function involves regulating various ion channels, receptors, and pumps, and is highly correlated with the key target information provided.
1. Adjust the voltage-gated ion channel (main target group)：
* Sodium ion channel (SCN5A/SCN1A)Cixi Ophiopogon Saponin A may have a mild to moderate use dependent blocking effect on the main sodium channel Nav1.5 (encoded by SCN5A) in the heart, inhibiting fast sodium current (INa), which helps to reduce the depolarization rate and conductivity of myocardial cells in phase 0, inhibit reentry formation, and is beneficial for the treatment of rapid arrhythmia.
* potassium ion channel：
* Fast Delay Rectified Potassium Channel (KCNH2/hERG)This channel mediates IKr current, which is one of the main currents in the third phase of action potential repolarization. It is interesting that although Cixi Ophiopogon Saponin A can prolong APD, the predicted data shows that it has no hERG inhibition, suggesting that it may not prolong APD by directly blocking hERG channels, but by affecting other repolarization currents or indirect mechanisms. This may be its potential safety advantage, as strong hERG blockade is the main cause of many synthetic drug-induced arrhythmias.
* Slow delay rectifier potassium channel (KCNQ1/KCNE1)This complex mediates IKs current. Research has shown that Cixi Ophiopogon Saponin A may stabilize APD and provide frequency dependent protective effects by enhancing IKs or regulating their dynamics during increased heart rate.
* Instantaneous outward potassium channel (KCNA5)Mediate Ito current and affect early repolarization of action potential (phase 1). Adjusting Ito may affect the morphology and plateau stability of APD.
* L-type calcium channel (CACNA1C)Cixi Ophiopogon Saponin A may have a certain inhibitory effect on L-type calcium current (ICa-L). Inhibition of ICa-L can reduce calcium influx and alleviate intracellular calcium overload, which not only helps to reduce the autonomy of the sinoatrial node and atrioventricular node, prolong their refractory period, but also counteract ischemia/reperfusion injury, and has multiple antiarrhythmic effects.
2. Regulating ligand gated ion channels and receptors：
* Nicotinic acetylcholine receptor alpha 7 subunit (CHRNA7)There is a cholinergic anti-inflammatory pathway in the heart. Activation of CHRNA7 may indirectly improve myocardial electrical stability by inhibiting inflammatory responses and oxidative stress, particularly in arrhythmias associated with myocardial infarction and heart failure.
* Muscarinic acetylcholine receptor M2 subtype (CHRM2)As the main cholinergic receptor in the heart, it mediates the vagus nerve effect. Regulating CHRM2 may affect the autonomic nervous tension of the heart, thereby regulating heart rate, conduction, and refractory period, and has certain therapeutic potential for sinus tachycardia, atrial fibrillation, and other conditions.
3. Adjust the ion pump：
* Sodium potassium ATPase (ATP1A1)Cixi Ophiopogon Saponin A may have a regulatory effect on Na+/K+- ATPase activity. Moderate inhibition of the pump can slightly increase intracellular Na+concentration, which in turn affects intracellular Ca2+concentration through Na+/Ca2+exchangers (NCX), ultimately regulating myocardial contractility and electrical activity. This regulation may be one of the mechanisms underlying its positive inotropic effect (as reported by some Ophiopogon saponins) and antiarrhythmic effect.
Summary Cixi Ophiopogon Saponin A balances the relationship between cardiac excitability and autonomy, conductivity and refractory period by synergistically regulating various ion flows such as Na+, K+, Ca2+, etc. It may also stabilize myocardial electrical activity in multiple dimensions and targets by affecting autonomic receptors and ion pumps. The APD prolongation mechanism of non hERG blockade is particularly worthy of further exploration and may represent a safer mode of antiarrhythmic action.
Evaluation of drug properties and pharmacokinetics
Based on calculations and preliminary experimental data, a preliminary evaluation of the pharmacological properties of Cixi Ophiopogon Saponin A is conducted
Advantage：
1. Clear activity and multi-target effect The anti arrhythmic effect is confirmed, and the multi-target characteristic may bring better efficacy and lower drug resistance.
2. High potential safety Predicting the absence of hERG inhibition and Ames mutagenicity is a significant advantage of it as a candidate antiarrhythmic drug, which may avoid the risk of arrhythmia associated with traditional drugs.
3. Natural source, novel structure As a natural product, its skeleton and sugar chain structure provide a new template for drug design.
challenge：
1. Solubility and permeability High TPSA and moderate LogP indicate that it belongs to the highly polar and low-permeability compounds in the Biopharmaceutical Classification System (BCS). This may result in lower oral bioavailability and poor intestinal absorption.
2. Metabolism and stability As glycoside compounds, they are easily hydrolyzed by microbial communities or digestive enzymes in the gastrointestinal tract, and their activity may change or be lost after losing their sugar chains. Phase II metabolism (such as glucuronidation and sulfation) is also prone to occur in the body.
3. Pharmacokinetic properties unknown Currently, there are few systematic research reports on its absorption, distribution, metabolism, and excretion (ADME) process in the body. The key pharmacokinetic parameters such as plasma protein binding rate, tissue distribution characteristics, major metabolites, and elimination half-life urgently need to be clarified.
Improvement strategy：
To enhance its medicinal properties, future research may consider:
* Prodrug strategy Modify the hydroxyl groups on the sugar chain through esterification, acylation, and other methods to prepare lipophilic prodrugs, improve their membrane permeability and oral absorption, and then hydrolyze them into the original drug in vivo.
* New drug delivery system Develop delivery systems such as liposomes, nanoparticles, and self microemulsions to improve their solubility, protect them from gastrointestinal degradation, and potentially achieve targeted delivery.
* Simplification and optimization of structure Based on its active parent nucleus ophiogenin and key glycosylation structure, a systematic structure-activity relationship study was conducted to synthesize and screen simplified analogues with better activity and pharmacokinetic properties.
Clinical application prospects and prospects
Cixi Ophiopogon Saponin A, as a natural antiarrhythmic lead compound with unique structure and multi-target effects, has broad clinical application prospects, but the road ahead is long.
Potential application directions：
1. Development of new antiarrhythmic drugs The most direct direction is to develop it into an injectable or orally modified formulation for the treatment of common arrhythmias such as premature ventricular contractions, ventricular tachycardia, and atrial fibrillation. Its multi-target characteristics may be applicable to complex arrhythmias.
2. Adjuvant therapy for myocardial ischemia/reperfusion injury By utilizing its dual effects of antiarrhythmic and myocardial protection, it can be used as an adjuvant medication in acute myocardial infarction reperfusion therapy to prevent reperfusion arrhythmia and protect myocardial function.
3. Modernization of Traditional Chinese Medicine and Quality Markers In depth research on the role and contribution of Cixi Ophiopogon Saponin A in the overall efficacy of Ophiopogon japonicus medicinal materials can provide scientific basis for its use as a quality control marker for Ophiopogon japonicus medicinal materials and their formulations (such as Shengmai San and Shenmai Injection), and promote the standardization and internationalization of traditional Chinese medicine.
Future research prospects：
1. In depth mechanism research Using techniques such as molecular docking, surface plasmon resonance, and cryo electron microscopy, clarify the direct binding sites and modes of action with key targets such as KCNQ1 and CACNA1C. Using genetically modified animals or specific knockdown/overexpression cell models, verify the contribution of each target in the overall efficacy.
2. Systematic pharmacokinetic study Conduct comprehensive preclinical ADME studies to clarify its absolute bioavailability, major metabolic pathways, active metabolites, tissue distribution, and excretion patterns.
3. Preclinical safety evaluation After completing preliminary pharmacological and pharmacokinetic studies, it is necessary to conduct systematic safety evaluations such as acute toxicity, long-term toxicity, and reproductive toxicity in accordance with new drug development standards, and comprehensively evaluate its treatment window.
4. Pharmaceutical research and optimization Actively developing new drug delivery systems to address the shortcomings in their physical and chemical properties is a key step in promoting their clinical application.
5. Exploring the potential of combination therapy Study whether the combination of it with existing antiarrhythmic drugs such as beta blockers and amiodarone can produce synergistic effects while reducing their respective doses and side effects.
Conclusion
Cixi Ophiopogon Saponin A is a highly valuable furostanol type saponin discovered from traditional Chinese medicine Ophiopogon japonicus. It has a novel structure and clear pharmacological activity, demonstrating significant protective effects in various arrhythmia models. Of particular importance, its predictions and preliminary studies suggest that it may have a safer multi-target mechanism of action than traditional drugs, especially its potential "non hERG blocking" properties, providing new ideas for the development of highly efficient and low toxicity new antiarrhythmic drugs. However, its inherent pharmaceutical challenges, such as poor solubility and potential poor oral absorption, are technical difficulties that must be overcome in future translational research. Through in-depth molecular mechanism elucidation, systematic pharmacokinetic studies, and innovative pharmaceutical strategies, Cixi Ophiopogon Saponin A is expected to gradually move from an excellent natural lead compound to clinical practice, bringing new treatment options for arrhythmia patients and providing a model for the modernization research of active ingredients in traditional Chinese medicine.
![Ophiogenin 3-O-α-L-rhamnopyranosyl(1→2)[β-D-xylopyranosyl(1→3)]-β-D-glucopyranoside](/upload/0201/01/288143-27-1.png)
